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SCREENING PROGRAMME IS POTENTIALLY COST-EFFECTIVE
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OBJECTIVES: A vaccine to prevent infection with human papil-
lomavirus (HPV) types 6, 11, 16 and 18 may soon become avail-
able. The current strategy to prevent cervical cancer in the UK
is screening every 3 years, beginning at age 25 and then every 5
years for women aged 50+. The current screening coverage rate
is 81.2%. The objectives are to assess the health and economic
impact of HPV vaccination in association with current screening
in the UK compared to screening alone. METHODS: A Markov
model of the natural history of HPV infection incorporating
screening and vaccination was developed for the UK. A vaccine
that would prevent 90% of HPV 6, 11, 16 and 18-associated
disease, with 20 years duration and 87% coverage, given to girls
at age 12 in conjunction with current screening was compared
to screening alone using cost per life-year (LY) and quality-
adjusted life-year (QALY). Sensitivity analyses included varying
the vaccination cost from £165 to £220 and assuming a lifetime
duration for vaccine efﬁcacy. RESULTS: The model predicts the
reduction in lifetime risk of cervical cancer attributable to screen-
ing in line with already published UK data. Introduction of vac-
cination, and maintaining the screening programme unchanged,
would be expected to reduce the lifetime risk to 0.66%. Vacci-
nation with current screening is associated with an incremental
cost-effectiveness ratio (ICER) that varies from £16,000/QALY
(£20,600/LY) to £22,000/QALY (£28,200/LY) compared to
screening alone, when the vaccination cost is varied from £165
to £220. If a lifetime duration of vaccine efﬁcacy is assumed, the
ranges for the ICERs decrease to £12,750/QALY (£16,250/LY)
and £17,570/QALY (£22,400/LY) respectively. CONCLUSION:
These analyses suggest that adding a quadrivalent HPV vaccine
to current screening in the UK may be a cost-effective method
for further reducing the burden of cervical cancer.
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PRELIMINARY COST-EFFECTIVENESS ANALYSIS OF A
POTENTIAL PROPHYLACTIC STHAPHYLOCOCCUS AUREUS
VACCINE (STAPHVAX) IN HEMODIALYSIS PATIENTS IN
GERMANY
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1Premor Associates, New York, NY, USA; 2Premor Associates, Madrid,
Spain
OBJECTIVE: Increasing antibiotic resistant staphylococcus
aureus strains in hospital- and chronic disease patients causing
a high burden of illness and consume enormous health care
resources in Germany. A new vaccine (StapVax) preventing
S.aureus infections is in clinical development and currently
seeking market authorization in the EU. The objective of this
analysis is to project the potential economic value of vaccinat-
ing hemodialysis patients with StapVax against mecillin resistant
staphylococcus aureus infections. METHODS: A literature-
based decision analysis model was developed to assess the annual
number of potential infections and death avoided as well as to
calculate cost-effectiveness, break-even price and budget impact
of the candidate vaccine. Baseline efﬁcacy rate was assumed to
be 57% with a 90% coverage rate. The model compared pro-
jected cost per infection avoided and cost per life-year gained for
patients receiving the vaccine versus unvaccinated patients
undergoing hemodialysis. RESULTS: Vaccinating the about
60,000 hemodialysis patients in Germany could prevent 650
S.aureus infections and 105 associated deaths per year. Assum-
ing annual per patient vaccination cost of €500 (vaccine plus
administration) the cost per infection avoided was estimated at
€27,000, with a cost per life-year gained of €17,000, respectively.
The net-budget impact in this scenario results in about €18
million. Vaccination cost of €170 would make the vaccine a
budget neutral preventive strategy. Monte Carlo simulations on
vaccine efﬁcacy, mortality rate after S.aureus infection, treatment
and vaccination cost resulted in cost per life-year gained ranging
from €3000 to €22,000 in 95% of the runs, and from €7000 to
€14,000 in 50% of trial runs. The model is most sensitive to
vaccine program cost and predicted preventive efﬁcacy. CON-
CLUSION: Vaccinating hemodialysis patients with StaphVax is
a highly cost-effective measure to prevent serious morbidity and
mortality in this patient population at substantial risk of bacte-
rial contamination.
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COST-EFFECTIVENESS OF PREVENTING OF RECURRENT
UPPER RESPIRATORY TRACT INFECTIONS WITH NON-
SPECIFIC IMMUNOSTIMULATING BACTERIAL EXTRACT
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OBJECTIVES: To estimate the pharmacoeconomic impact of
preventing recurrent upper respiratory tract infections (URTIs)
with OM-85, a non-speciﬁc immunostimulating agent, in at-risk
children. METHODS: Implementation of a decisional model.
The evaluation of effectiveness (number of prevented
URTIs/therapeutic cycle) was based on weighted average of the
results of four randomized, double-blind, placebo-controlled
trials identiﬁed by literature reviewing. The clinical events con-
sidered in the model were natural resolution of the infection,
onset of complications (acute otitis media, sinusitis, others) and
their evolution. Baseline event probabilities were derived by
reviewing published data in the literature. URTI-related direct
and indirect costs supported by patients, by Italian health system
and by community were structured according with the principal
guidelines and implemented with current Italian prices and
tariffs. The cost-effectiveness of OM-85 was calculated for ﬁve
scenarios, differing in the number of therapeutic cycles, grade of
patient co-payment and other secondary assumptions. Sensibil-
ity analyses were performed to evaluate the model robustness.
RESULTS: Immunostimulation with one cycle of OM-85 pre-
vented on average 1.60 URTI/patient in 6 months (RR = 0.515).
In the basic scenario, this preventive action induced savings for
€107.42/patient in the perspective of the patient’s family, for
€48.52/patient in the perspective of Italian health system and for
231.26 in the community perspective. Sensibility analyses con-
ﬁrmed the robustness of basic scenario results. Threshold analy-
ses showed that OM-85 prophylaxis is economically convenient
as long as more than 7% of infections are prevented or global
cost of one episode of URTI is greater than €10.00. CONCLU-
SIONS: Non-speciﬁc immunotherapy with OM-85 induces a
reduction in the incidence of URTIs in at-risk children with a
concurrent saving for patients and health system.
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OBJECTIVE: There are no pharmacoeconomic studies perform
to date comparing voriconazole and liposomal Amphotericin B
(LAB) for the treatment of systemic fungal infections. The aim
of this study was to perform an economic evaluation of voricona-
zole versus LAB for the treatment of invasive aspergillosis and
candidiasis. METHODS: A cost-minimization analysis was per-
formed from the hospital perspective in 2005, as the same efﬁ-
cacy was assumed. A systematic review of available literature
was performed between 1996 and 2005, in order to obtain the
efﬁcacy and incidence of drug-related adverse events (AE) for
each treatment group. Duration of treatment (intravenous: 15.42
days; oral: 4.49 days; the same for both treatments) and mean
weight of patients (68.6Kg) were obtained from a local study:
The Fungcost study (Peiro S. Value Health 2002;5:564). Only
direct costs per episode were considered; medications (iv and
oral) at their hospital selling prices; the cost of monitoring AE;
and administration costs (obtained from a national cost data-
base). Voriconazol was the oral treatment in both groups. The
most important AE for each treatment (and the way to monitor
them) were: hepatotoxicity with voriconazole -13.97%—(two
chemistries and hematologic tests during the treatment period);
and nefrotoxicity with LAB -12.84%—(a daily creatinine clear-
ance measurement). Mean cost per episode and incremental cost
were calculated. RESULTS: Mean cost per episode was €6073.43
(iv treatment 94.22%) for voriconazole, and €8794.33 (iv:
95.78%) for LAB in the treatment of invasive aspergillosis, with
an incremental cost of €2486.90 (28.28%) The treatment of can-
didiasis showed a mean cost of €6307.43 (iv: 94.22%) and
€8779.92 (95.93%), respectively, with an incremental cost of
€2472.48 (28.16%). Results were robust to the sensitivity analy-
sis. CONCLUSION: Using costs and treatment patterns of
fungal infections in Spain, voriconazole is more cost-effective
than LAB for the treatment of invasive candidiasis and
aspergillosis.
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OBJECTIVE: Human Papillomavirus infection is the principal
cause of cervical cancer and most cervical neoplasia. Despite
available screening and treatment, cervical cancer remains an
important public health problem. HPV vaccination studies have
shown high efﬁcacy against HPV-induced cervical lesions. Prior
to implementing a vaccination programme, data about cervical
dysplasia and annual treatment costs are critical. This study
assessed resource use and costs for Pap III, IIID and IV patients
in Germany. METHODS: A one-year retrospective chart review
of 138 patients, diagnosed with Pap III, IIID or IV between Feb-
ruary—March 2004, was conducted to assess clinical and
resource use. Resources included consultations, medications,
procedures, diagnostics, adverse events and hospital stays. Unit
costs from ofﬁcial sources were applied to calculate the average
cost per patient. RESULTS: Most patients had Pap IIID (n = 79)
vs. Pap III (n = 27) or Pap IV (n = 32). Mean duration of treat-
ment was 4.4, 5.5, and 4.9 months for Pap III, IIID and IV
respectively. Pap IIID patients had on average 4.6 gynaecologist
consultations vs. 4.2 and 5.6 for Pap III and IV respectively. Most
common diagnostic tests were Pap-smears (99%) and col-
poscopy (in 89%, 73% and 75% of Pap III, IIID and IV). Typ-
ically, patients were treated by conisation (in 22%, 27% and
84% of Pap III, IIID and IV). More Pap IV patients had hys-
terectomies (22% vs. 4% for Pap III) and laser coagulation
(12.5% vs. 4% for Pap IIID). 33% of the patients were hospi-
talised (mean 7.4 ± 8.3 days). The estimated average annual cost
per patient was €1070, €955 and €3240 for Pap III, IIID and Pap
IV, including 40% indirect costs. CONCLUSION: The cost of
managing pre-cancerous cervical lesions in Germany is high. An
HPV vaccine preventing many of these lesions could avert much
of these costs.
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ESTIMATED ANNUAL NHS COSTS OF HUMAN
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OBJECTIVE: Human Papillomavirus (HPV) is the main cause
of genital warts (GWs) and a necessary cause of cervical cancer
(CC). There is a lifetime HPV infection risk in women of
55–75%. Genitourinary Medicine (GUM) clinics and CC screen-
ing programmes help in the detection and treatment of GWs and
deceleration of progression to cancerous lesions. This study esti-
mated the annual National Health Service (NHS) costs of diag-
nosing and managing HPV related diseases in a pre-HPV vaccine
era. METHODS: Data for ﬁrst and recurrent GWs episodes were
obtained from the Health Protection Agency and management
pathways from GUM clinicians. The number of women screened
for CC, results, and procedures undertaken for abnormal ﬁnd-
ings were obtained from a variety of sources (e.g., Government
Statistical Service, Regional Screening Programmes; adjusted to
2003). Annual new cases of CC were obtained from GLOBO-
CAN, 2002. Resource costs (2003) included screening tests, clin-
ician visits, diagnostic and treatment procedures, hospital
admissions and drugs. Sensitivity analyses examined the range of
treatment patterns and costs. RESULTS: In 2003, GUM clinics
treated almost 114,000 patients with GWs. Topical creams were
the ﬁrst line treatment for the majority (77%) followed by
cryotherapy or combination of the two. An average 26% of
patients returned to complete their treatment. Total annual costs
for GWs were £22.4 million. In 2003, 4.8 million CC screening
tests were conducted at a cost of £104.5 million. Over 227,209
women were referred for colposcopy, costing £34 million for the
diagnosis and treatment of precancerous lesions. Newly identi-
ﬁed CC cases (N = 3308) and hospital admissions for prevalent
CC cases in 2003 cost £43.7 million. Estimated total 2003 NHS
costs related to HPV were £204.6 million (range: £181.3–£209.7
million). CONCLUSION: Preventing HPV related diseases
through vaccination with a quadrivalent vaccine could result in
cost offsets and more efﬁcient resource allocation.
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OBJECTIVES: Human Papillomavirus (HPV) infections, includ-
ing genital warts (GW), are common. Current treatments are not
